Boehringer Ingelheim's Spiolto Respimat improves quality of life for COPD patients

18 August 2015
boehringer-ingelheim-big

New data has shown that Spiolto Respimat (tiotropium/olodaterol) from German family-owned pharma major Boehringer Ingelheim provides meaningful quality of life improvements for chronic obstructive pulmonary disease (COPD).

The OTEMTO trials show that Spiolto Respimat provides clinically meaningful >4 point reduction in the St George’s Respiratory Questionnaire (SGRQ) score compared to placebo, which represents a significant improvement in quality of life for COPD patients.

As there is no cure for COPD, improving quality of life is a major goal of treatment, and is measured using the SGRQ. Reduction of the SGRQ score by 4 points or more is deemed clinically meaningful. The OTEMTO trials show that Spiolto Respimat provides a reduction of 4.67 points versus placebo.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical